Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Original Paper

Macular Pigment Optical Density in an Ageing Irish Population: The Irish Longitudinal Study on Ageing

Nolan J.M.a, b · Kenny R.c · O’Regan C.c · Cronin H.c · Loughman J.d · Connolly E.E.a, b · Kearney P.c · Loane E.a · Beatty S.a, b

Author affiliations

aMacular Pigment Research Group, Department of Chemical and Life Sciences, Waterford Institute of Technology, and bInstitute of Vision Research, Whitfield Clinic, Waterford, cTILDA Research Group, University of Dublin, and dMacular Pigment Research Group, Optometry Department, Dublin Institute of Technology, Dublin, Ireland

Related Articles for ""

Ophthalmic Res 2010;44:131–139

Do you have an account?

Login Information





Contact Information










I have read the Karger Terms and Conditions and agree.



Login Information





Contact Information










I have read the Karger Terms and Conditions and agree.



To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.
Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00


Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: June 04, 2009
Accepted: November 11, 2009
Published online: June 02, 2010
Issue release date: July 2010

Number of Print Pages: 9
Number of Figures: 5
Number of Tables: 2

ISSN: 0030-3747 (Print)
eISSN: 1423-0259 (Online)

For additional information: https://www.karger.com/ORE

Abstract

Purpose: The 3 carotenoids lutein, zeaxanthin, and meso-zeaxanthin, which account for the ‘yellow spot’ at the macula and which are referred to as macular pigment (MP), are believed to play a role in visual function and protect against age-related macular degeneration (AMD) via their optical and antioxidant properties. This study was undertaken to compare MP optical density (MPOD) in a population aged ≧50 years with MPOD values from a normative database of subjects aged 18–60 years. Methods: Seventy-nine subjects were recruited into this pilot study (The Irish Longitudinal Study on Ageing-TILDA). MPOD was measured using heterochromatic flicker photometry. Retinal fundus photographs, lifestyle data and general health data, were also obtained. Results: The mean ± SD age of the 79 subjects recruited into this study was 65 ± 11 years. There was a moderate, but statistically significant, age-related decline in MPOD at 0.5° in the TILDA data (r = –0.251, p = 0.045), which remained upon merging with a normative database of an additional 462 subjects aged between 18 and 67 years (r = –0.179, p = 0.000). Conclusions: We report an inverse association between MPOD and increasing age. Longitudinal data in a larger cohort of participants are required to satisfactorily investigate the relationship between the optical density of this pigment and age, and with risk for development and/or progression of AMD. This pilot study represents a first step in this endeavour.

© 2010 S. Karger AG, Basel


References

  1. Bressler NM: Age-related macular degeneration is the leading cause of blindness.. JAMA 2004;291:1900–1901.
  2. Congdon NG, Friedman DS, Lietman T: Important causes of visual impairment in the world today. JAMA 2003;290:2057–2060.
  3. Kelliher C, Kenny D, O’Brien C: Trends in blind registration in the adult population of the Republic of Ireland 1996–2003. Br J Ophthalmol 2006;90:367–371.
  4. Bunce C, Wormald R: Causes of blind certifications in England and Wales: April 1999–March 2000. Eye 2008;22:905–911.
  5. van Leeuwen R, Klaver CC, Vingerling JR, Hofman A, de Jong PT: Epidemiology of age-related maculopathy: a review. Eur J Epidemiol 2003;18:845–854.
  6. Augustin A, Sahel JA, Bandello F, Dardennes R, Maurel F, Negrini C, et al: Anxiety and depression prevalence rates in age-related macular degeneration. Invest Ophthalmol Vis Sci 2007;48:1498–1503.
  7. Bandello F, Lafuma A, Berdeaux G: Public health impact of neovascular age-related macular degeneration treatments extrapolated from visual acuity. Invest Ophthalmol Vis Sci 2007;48:96–103.
  8. Sommerburg O, Keunen JEE, Bird AC, van Kuijk FJGM: Fruits and vegetables that are sources for lutein and zeaxanthin: the macular pigment in human eyes. Br J Ophthalmol 1998;82:907–910.
  9. Maoka T, Arai A, Shimizu M, Matsuno T: The first isolation of enantiomeric and meso-zeaxanthin in nature. Comp Biochem Physiol B 1986;83:121–124.
  10. Beatty S, Koh HH, Henson D, Boulton M: The role of oxidative stress in the pathogenesis of age-related macular degeneration. Surv Ophthalmol 2000;45:115–134.
  11. Klein R, Klein BEK, Linton KLP: Prevalence of age-related maculopathy – the Beaver Dam Eye Study. Ophthalmology 1992;99:933–943.
  12. Klein R, Klein BEK, Jensen SC, Meuer SM: The five-year incidence and progression of age-related maculopathy – The Beaver Dam eye study. Ophthalmology 1997;104:7–21.
  13. Nolan JM, Stack J, O’Donovan O, Loane E, Beatty S: Risk factors for age-related maculopathy are associated with a relative lack of macular pigment. Exp Eye Res 2007;84:61–74.
  14. Whelan BJ: RANSAM: a random sample design for Ireland. Econ Soc Rev 1979;10:161–174.
  15. Wooten BR, Hammond BR, Land RI, Snodderly DM: A practical method for measuring macular pigment optical density. Invest Ophthalmol Vis Sci 1999;40:2481–2489.
  16. Stringham JM, Hammond BR, Nolan JM, Wooten BR, Mammen A, Smollon W, et al: The utility of using customized heterochromatic flicker photometry (cHFP) to measure macular pigment in patients with age-related macular degeneration. Exp Eye Res 2008;87:445–453.
  17. Falsini B, Fadda A, Iarossi G, Piccardi M, Canu D, Minnella A, et al: Retinal sensitivity to flicker modulation: reduced by early age-related maculopathy. Invest Ophthalmol Vis Sci 2000;41:1498–1506.
  18. Tyler CW: Two processes control variations in flicker sensitivity over the life span. J Opt Soc Am A 1989;6:481–490.
  19. Kirby ML, Galea M, Loane E, Stack J, Beatty S, Nolan JM: Foveal anatomic associations with the secondary peak and the slope of the macular pigment spatial profile. Invest Ophthalmol Vis Sci 2009;50:1383–1391.
  20. Berendschot TTJM, van Norren D: Macular pigment shows ringlike structures. Invest Ophthalmol Vis Sci 2006;47:709–714.
  21. Ciulla TA, Curran-Celantano J, Cooper DA, Hammond BR, Danis RP, Pratt LM, et al: Macular pigment optical density in a midwestern sample. Ophthalmology 2001;108:730–737.
  22. Hammond BR, Caruso-Avery M: Macular pigment optical density in a southwestern sample. Invest Ophthalmol Vis Sci 2000;41:1492–1497.
  23. Mellerio J, Ahmadi-Lari S, van Kuijk FJGM, Pauleikhoff D, Bird AC, Marshall J: A portable instrument for measuring macular pigment with central fixation. Curr Eye Res 2002;25:37–47.
  24. Liew M, Gilbert C, Spector TD, Mellerio J, van Kuijk FJGM, Beatty S, et al: Central retinal thickness is positively related to macular pigment optical density. Exp Eye Res 2006;82:915–920.
  25. Berendschot TTJM, van Norren D: On the age dependency of the macular pigment optical density. Exp Eye Res 2005;81:602–609.
  26. Loane E, Kelliher C, Beatty S, Nolan JM: The rationale and evidence base for a protective role of macular pigment in age-related maculopathy. Br J Ophthalmol 2008;92:1163–1168.
  27. Snodderly DM, Brown PK, Delori FC, Auran JD: The macular pigment.1. Absorbance spectra, localization, and discrimination from other yellow pigments in primate retinas. Invest Ophthalmol Vis Sci 1984;25:660–673.
  28. Broekmans WMR, Berendschot TTJM, Klopping-Ketelaars IAA, de Vries AJ, Goldbohm RA, Tijburg LBM, et al: Macular pigment density in relation to serum and adipose tissue concentrations of lutein and serum concentrations of zeaxanthin. Am J Clin Nutr 2002;76:595–603.
  29. Nolan JM, Stack J, O’Connell E, Beatty S: The relationships between macular pigment optical density and its constituent carotenoids in diet and serum. Invest Ophthalmol Vis Sci 2007;48:571–582.
  30. Caruso-Averi M, Perez J, Myers-Evitt MJ, Crosley R, Nenez G, Alexander B, et al: Factors related to individual differences in macular pigment optical density in a southwestern sample. Invest Ophthalmol Vis Sci 1999;40:888B848.
  31. Hammond BR, Ciulla TA, Snodderly DM: Macular pigment density is reduced in obese subjects. Invest Ophthalmol Vis Sci 2002;43:47–50.
  32. Hammond BR, CurranCelentano J, Judd S, Fuld K, Krinsky NI, Wooten BR, et al: Sex differences in macular pigment optical density: relation to plasma carotenoid concentrations and dietary patterns. Vision Rese 1996;36:2001–2012.
  33. Hammond BR, Fuld K, Snodderly DM: Iris color and macular pigment optical density. Exp Eye Res 1996;62:293–297.
  34. Nolan J, O’Donovan O, Kavanagh K, Stack J, Harrison M, Muldoon A, et al: Macular pigment and percentage of body fat. Invest Ophthalmol Vis Sci 2004;45:3940–3950.
  35. Curran-Celentano J, Hammond BR, Ciulla TA, Cooper DA, Pratt LM, Danis RB: Relation between dietary intake, serum concentrations, and retinal concentrations of lutein and zeaxanthin in adults in a Midwest population. Am J Clin Nutr 2001;74:796–802.
  36. Mares JA, Larowe TL, Snodderly DM, Moeller SM, Gruber MJ, Klein ML, et al: Predictors of optical density of lutein and zeaxanthin in retinas of older women in the Carotenoids in Age-Related Eye Disease Study, an ancillary study of the Women’s Health Initiative. Am J Clin Nutr 2006;84:1107–1122.
  37. Beatty S, Murray IJ, Henson DB, Carden D, Koh HH, Boulton ME: Macular pigment and risk for age-related macular degeneration in subjects from a Northern European population. Invest Ophthalmol Vis Sci 2001;42:439–446.
  38. Loane E, Nolan JM, O’Donovan O, Bhosale P, Bernstein PS, Beatty S: Transport and retinal capture of lutein and zeaxanthin with reference to age-related macular degeneration. Surv Ophthalmol 2008;53:68–81.
  39. Beatty S, Koh HH, Murray IJ, Henson DB, Boulton M: Macular pigment optical density and the risk for age-related macular degeneration. Invest Ophthalmol Vis Sci 2000;41:3187B285.
  40. Werner JS, Donnelly SK, Kliegl R: Aging and human macular pigment density. Appended with translations from the work of Max Schultze and Ewald Hering. Vision Res 1987;27:275–268.
    External Resources
  41. Delori FC, Goger DG, Hammond BR, Snodderly DM, Burns SA: Macular pigment density measured by autofluorescence spectrometry: comparison with reflectometry and heterochromatic flicker photometry. J Opt Soc Am A Opt Image Sci Vis 2001;18:1212–1230.
  42. Neelam K, O’Gorman N, Nolan J, O’Donovan O, Wong HB, Eong KGA, et al: Measurement of macular pigment: Raman spectroscopy versus heterochromatic flicker photometry. Invest Ophthalmol Vis Sci 2005;46:1023–1032.
  43. Ciulla TA, Hammond BR: Macular pigment density and aging, assessed in the normal elderly and those with cataracts and age-related macular degeneration. Am J Ophthalmol 2004;138:582–587.
  44. Bernstein PS, Zhao DY, Sharifzadeh M, Ermakov IV, Gellermann W: Resonance Raman measurement of macular carotenoids in the living human eye. Arch Biochem Biophys 2004;430:163–169.
  45. Liew SHM, Gilbert CE, Spector TD, Mellerio J, Marshall J, van Kuijk FJGM, et al: Heritability of macular pigment: a twin study. Invest Ophthalmol Vis Sci 2005;46:4430–4436.
  46. Iannaccone A, Mura M, Gallaher KT, Johnson EJ, Todd WA, Kenyon E, et al: Macular pigment optical density in the elderly: findings in a large biracial Midsouth population sample. Invest Ophthalmol Vis Sci 2007;48:1458–1465.
  47. Richer S, Devenport J, Lang JC: LAST II: Differential temporal responses of macular pigment optical density in patients with atrophic age-related macular degeneration to dietary supplementation with xanthophylls. Optometry 2007;78:213–219.
    External Resources
  48. van der Veen RL, Ostendorf S, Hendrikse F, Berendschot TT: Macular pigment optical density relates to foveal thickness. Eur J Ophthalmol 2009;19:836–841.
  49. Kilbride PE, Alexander KR, Fishman M, Fishman GA: Human macular pigment assessed by imaging fundus reflectometry. Vision Res 1989;29:663–674.
  50. Chen SF, Chang Y, Wu JC: The spatial distribution of macular pigment in humans. Curr Eye Res 2001;23:422–434.
  51. Berendschot TTJM, Willemse-Assink JJM, Bastiaanse M, De Jong PTVM, van Norren D: Macular pigment and melanin in age-related maculopathy in a general population. Invest Ophthalmol Vis Sci 2002;43:1928–1932.
  52. Wustemeyer H, Moessner A, Jahn C, Wolf S: Macular pigment density in healthy subjects quantified with a modified confocal scanning laser ophthalmoscope. Graefes Arch Clin Exp Ophthalmol 2003;241:647–651.
  53. Berendschot TTJM, van Norren D: Objective determination of the macular pigment optical density using fundus reflectance spectroscopy. Arch Biochem Biophys 2004;430:149–155.
  54. Zagers NPA, van Norren D: Absorption of the eye lens and macular pigment derived from the reflectance of cone photoreceptors. J Opt Soc Am A Opt Image Sci Vis 2004;21:2257–2268.
  55. Trieschmann M, Beatty S, Nolan JM, Hense HW, Heimes B, Austermann U, et al: Changes in macular pigment optical density and serum concentrations of its constituent carotenoids following supplemental lutein and zeaxanthin: the LUNA study. Exp Eye Res 2007;84:718–728.
  56. Gellermann W, Ermakov IV, Ermakov MR, McClane RW, Zhao DY, Bernstein PS: In vivo resonant Raman measurment of macular pigments in the young and the aging human retina. J Opt Soc Am A Opt Image Sci Vis 2002;19:1172–1186.
  57. Bone RA, Landrum JT, Fernandez L, Tarsis SL: Analysis of the macular pigment by HPLC – retinal distribution and age study. Invest Ophthalmol Vis Sci 1988;29:843–849.
  58. Handelman GJ, Dratz EA, Reay CC, van Kuijk FJGM: Carotenoids in the human macula and whole retina. Invest Ophthalmol Vis Sci 1988;29:850–855.
  59. Bone RA, Landrum JT, Mayne ST, Gomez CM, Tibor SE, Twaroska EE: Macular pigment in donor eyes with and without AMD: A case-control study. Invest Ophthalmol Vis Sci 2001;42:235–240.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: June 04, 2009
Accepted: November 11, 2009
Published online: June 02, 2010
Issue release date: July 2010

Number of Print Pages: 9
Number of Figures: 5
Number of Tables: 2

ISSN: 0030-3747 (Print)
eISSN: 1423-0259 (Online)

For additional information: https://www.karger.com/ORE


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.